Defining myeloid-derived suppressor cells
Nat Rev Immunol
.
2024 Dec;24(12):850-857.
doi: 10.1038/s41577-024-01062-0.
Epub 2024 Jul 5.
Authors
Leila Akkari
1
,
Ido Amit
2
,
Vincenzo Bronte
3
,
Zvi G Fridlender
4
5
,
Dmitry I Gabrilovich
6
,
Florent Ginhoux
7
8
,
Catherine C Hedrick
9
10
11
,
Suzanne Ostrand-Rosenberg
12
13
Affiliations
1
Division of Tumour Biology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands. l.akkari@nki.nl.
2
Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel. ido.amit@weizmann.ac.il.
3
Instituto Oncologico Veneto IOV-IRCCS, Padua, Italy. vincenzo.bronte@iov.veneto.it.
4
Institute of Pulmonary Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. Fridlender@hadassah.org.il.
5
Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Fridlender@hadassah.org.il.
6
ICC, Early Oncology, AstraZeneca, Gaithersburg, MD, USA. dmitry.gabrilovich@astrazeneca.com.
7
Gustave Roussy Cancer Campus, Villejuif, France. florent.ginhoux@gustaveroussy.fr.
8
Paris-Saclay University, Paris, France. florent.ginhoux@gustaveroussy.fr.
9
Immunology Center of Georgia, Augusta University, Augusta, GA, USA. lhedrick@augusta.edu.
10
Georgia Cancer Center, Augusta University, Augusta, GA, USA. lhedrick@augusta.edu.
11
Department of Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA. lhedrick@augusta.edu.
12
Department of Pathology, University of Utah, Salt Lake City, UT, USA. srosenbe@umbc.edu.
13
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. srosenbe@umbc.edu.
PMID:
38969773
DOI:
10.1038/s41577-024-01062-0
No abstract available